Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 in Type 2 Diabetes
NCT05966272Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in type 2 diabetes mellitus (T2DM), sponsored by Fujian Shengdi Pharmaceuticals. Started Aug 2023; status: completed.
02
Drugs
HRS9531
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05966272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05966272.